The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
It promises fewer injections for vision loss patients
Call it a major breakthrough for diagnostic imaging
Subscribe To Our Newsletter & Stay Updated
